Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar’s healthcare perspective

Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar’s healthcare perspective

<h3>Objectives</h3><p dir="ltr">Treatment options for preventing vaso-occlusive crises among sickle cell disease patients are on the rise, especially if hydroxyurea treatment has failed. This economic analysis is conducted to assess the comparative clinical effectiveness,...

Full description

Saved in:
Bibliographic Details
Main Author: Ahmad M Adel (21767351) (author)
Other Authors: Dina Abushanab (10696501) (author), Daoud Al-Badriyeh (832403) (author), Anas Hamad (9545771) (author), Awni Alshurafa (15468195) (author), Mohamed A Yassin (14777224) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Pharmacology and pharmaceutical sciences
Health economics
Pharmacoeconomics
Cost-effectiveness analysis
Sickle cell disease
Vaso-occlusive crises
Hydroxyurea
L-glutamine
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items